Research & Development
Elanco to divest USD135m Osurnia animal health business
6 January 2020 -

Animal health company Elanco Animal Health Incorporated (NYSE:ELAN) said on Monday that it has entered into an agreement to sell its Osurnia animal health business to Dechra Pharmaceuticals PLC (LON:DPH) for USD135m in an all-cash deal.

Osurnia, which is used as a treatment for otitis externa in dogs, recorded annual revenue of USD31.2m 2018.

The proactive divestiture of Osurnia helps advance Bayer Animal Health acquisition anti-trust review. The closing of the transaction with Dechra is contingent on Elanco entering into a consent decree with the Federal Trade Commission (FTC), the European Commission (EU Commission) and other agencies in connection with its Bayer transaction, as well as other customary closing conditions.

Any proposed remedies and final clearance for the Elanco/Bayer transaction remain subject to review and approval from regulatory authorities.



Related Headlines